BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2016

View Archived Issues

Emulate enters translational R&D collaboration

Read More

Roche reviews highlights of third quarter 2016

Read More

TxCell and UBC begin strategic collaboration to develop CAR-Tregs in solid organ transplantation

Read More

BlackThorn Therapeutics closes series A financing

Read More

Merck & Co. patents BTK inhibitors

Read More

Rigel Pharmaceuticals discloses TGF-beta and/or GDF-8 inhibitors

Read More

MedImmune begins phase I study of anti-ILT-7 antibody

Read More

AbbVie describes TRPV3 receptor antagonists

Read More

FDA approves Zinplava to reduce recurrence of C. difficile infection

Read More

FDA approves updated labeling for Xtandi

Read More

Gilead Sciences reports results of three phase II studies of selonsertib

Read More

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Read More

Daiichi Sankyo updates decision on phase III study of pexidartinib in tenosynovial giant cell tumor

Read More

Bristol-Myers Squibb develops IDO inhibitors

Read More

Phase II results on OMS-721 in stem cell transplant-associated thrombotic microangiopathy

Read More

Daiichi Sankyo reports Japanese phase III results for prasugrel in ischemic cerebrovascular disease

Read More

Gilead Sciences provides results from phase III studies of sofosbuvir/velpatasvir/voxilaprevir

Read More

Phase III efficacy trials of revefenacin in COPD meet primary endpoint

Read More

NeuroVive and Arbutus terminate NVP-018 agreement

Read More

FDA committee votes in favor of approving SER-120 for nocturia

Read More

FDA accepts resubmitted NDA for safinamide

Read More

Phase III study of denosumab in MM meets primary enpoint

Read More

VBI-1901 shows promising preclinical results

Read More

GSK submits BLA for Shingrix

Read More

Janssen presents phase I results for ExPEC4v

Read More

Multiplatform imaging of systemic amyloidosis with the new peptide p5+14

Read More

New mutations in known disease-associated genes

Read More

Discovery of new biomarkers for conditions

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing